Welcome to the Library. The Library provides a selection of industry resources including eBooks, Whitepapers, Webinars, Survey Reports, Research Reports and more.
If you are interested in submitting items to the Library, please contact our advertising team
Library
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
eBook: Trends in Enterprise Content Management in BioPharma
All industries have their own ECM needs, but biopharma enterprises have specific challenges This ebook looks at how ECM has evolved, what the challenges to biopharma are, and how those challenges and obstacles are being met by a variety of ECM approaches. Download Today.
Achieving Proof-of-Concept Data for Inflammation Drug Studies
FierceBiotech will hosted a one-hour webinar with top clinical investigators who shared their insights on the new technologies and strategies now in play to help improve studies for drugs in the inflammation field. Their ideas are relevant for everyone in the R&D world. Register Today!
Supplying Global Clinical Trials: Keys to Avoiding Costly Delays
This FierceBiotech eBook provides expert analysis and industry insights to guide biopharma professionals that face the challenges of meeting strict timelines, selecting contractors and avoiding setbacks during the planning and execution of manufacturing partnerships for global clinical trials. Download Now.
Next Gen Sequencing from FFPE Samples
Next generation sequencing (NGS) technologies hold enormous promise to advance personalized medicine applications in cancer. However, challenging real-world tumor specimens such as FFPE and FNA specimens have not yet been carefully addressed by NGS procedures. We developed two complementary and scalable PCR-based target enrichment methods for amplifying dozens to thousands of cancer gene loci in FFPE specimens with compatibility for both Illumina and Ion Torrent NGS. These methods enabled uniform read coverage, high depth sequencing (1000-30,000X), low background error rates, high sensitivity mutation detection (to 1-3% variants), and excellent concordance with Sanger sequencing and other mutation confirmation methods. Watch now.
Biosimilar regulations and CMOs
Biosimilar legislation passed in 2010 guaranteed 12 years of patent protection to biotechs from biosimilar competition. But passing the law was the easy part. As FDA hashes out regulations to implement the law, we help CMOs understand the significance of the legislation to their businesses and how the new legislation may help, or hurt, contract manufacturing for biologics. Register today.
FierceBiotech Special Report: The Future of Biopharma Manufacturing
Biotech and pharma manufacturing have reached a tipping point. Pricing pressures, generic competition, the push toward personalized medicine--all of these market forces are conspiring to change drugmaking processes for good. Addressing these trends will require a mixture of technologies and some mental shifts, too. This FierceBiotech special report outlines new technologies companies are using to make these improvements.
Latest Commentary